PL2785739T3 - Poprawa wyniku trabekulektomii - Google Patents

Poprawa wyniku trabekulektomii

Info

Publication number
PL2785739T3
PL2785739T3 PL12797862T PL12797862T PL2785739T3 PL 2785739 T3 PL2785739 T3 PL 2785739T3 PL 12797862 T PL12797862 T PL 12797862T PL 12797862 T PL12797862 T PL 12797862T PL 2785739 T3 PL2785739 T3 PL 2785739T3
Authority
PL
Poland
Prior art keywords
trabeculectomy
outcome
improving
trabeculectomy outcome
improving trabeculectomy
Prior art date
Application number
PL12797862T
Other languages
English (en)
Inventor
Bart Jonckx
Bergen Tine Van
Ingeborg Stalmans
Original Assignee
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics Nv filed Critical Thrombogenics Nv
Publication of PL2785739T3 publication Critical patent/PL2785739T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
PL12797862T 2011-12-01 2012-12-03 Poprawa wyniku trabekulektomii PL2785739T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565676P 2011-12-01 2011-12-01
PCT/EP2012/074195 WO2013079713A1 (en) 2011-12-01 2012-12-03 Improving trabeculectomy outcome
EP12797862.5A EP2785739B1 (en) 2011-12-01 2012-12-03 Improving trabeculectomy outcome

Publications (1)

Publication Number Publication Date
PL2785739T3 true PL2785739T3 (pl) 2017-10-31

Family

ID=47297234

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12797862T PL2785739T3 (pl) 2011-12-01 2012-12-03 Poprawa wyniku trabekulektomii

Country Status (7)

Country Link
US (1) US9089552B2 (pl)
EP (1) EP2785739B1 (pl)
AU (1) AU2012321082B2 (pl)
DK (1) DK2785739T3 (pl)
ES (1) ES2628321T3 (pl)
PL (1) PL2785739T3 (pl)
WO (1) WO2013079713A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104383180A (zh) * 2014-10-28 2015-03-04 王盛兴 治疗带状疱疹的药物及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IT1242149B (it) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
WO1993020229A1 (en) 1992-04-03 1993-10-14 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CA2235685A1 (en) 1995-10-23 1997-05-01 Hyal Pharmaceutical Australia Limited Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
EP0928203B1 (en) 1996-09-24 2006-10-25 Merck & Co., Inc. Compounds for the inhibition of angiogenesis by gene therapy
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
AU758353B2 (en) 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
EP1079688A1 (en) 1998-05-26 2001-03-07 Innogenetics N.V. Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
ATE356201T1 (de) 1999-07-14 2007-03-15 D Collen Res Foundation Vzw Monoklonaler antikörper der faktor viii selbst in molarem überschuss nur teilweise inaktiviert und eine methode zur herstellung solch eines antikörpers
JP2001086982A (ja) 1999-07-16 2001-04-03 Shunpei Niida 骨吸収調節薬
AU2001228742A1 (en) 2000-02-04 2001-08-14 Supratek Pharma, Inc. Ligand for vascular endothelial growth factor receptor
AU2001265953B2 (en) 2000-05-12 2005-09-29 D. Collen Research Foundation Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
CA2450954A1 (en) 2001-06-20 2003-01-03 Imclone Systems Incorporated Method of treating atherosclerosis and other inflammatory diseases
ATE347908T1 (de) 2002-01-29 2007-01-15 Vlaams Interuniv Inst Biotech Vorbeugung von gewebeadhäsion
AU2003251397B2 (en) 2002-06-05 2009-10-01 Genentech, Inc. Compositions and methods for liver growth and liver protection
CA2491053A1 (en) 2002-06-28 2004-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of antibodies against flt-1 for the treatment of osteoporosis
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
ES2412489T3 (es) 2003-08-14 2013-07-11 Thrombogenics N.V. Anticuerpos contra el factor VIII con glucosilación modificada en la región variable
ES2565481T3 (es) * 2005-03-24 2016-04-05 Thrombogenics N.V. Anticuerpo anti-PlGF novedoso
US7867490B2 (en) 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
WO2009067407A2 (en) 2007-11-19 2009-05-28 Bausch & Lomb Incorporated Compositions of matrix metalloproteinase activating endopeptidases for reducing intraocular pressure, and methods of use thereof
WO2009073457A1 (en) 2007-11-30 2009-06-11 Bausch & Lomb Incorporated Methods and compositions for the rescue of a filtering bleb
KR101798664B1 (ko) 2008-10-02 2017-11-16 브이아이비 브이지더블유 필라델피아 염색체 양성 백혈병의 치료를 위한 피엘지에프의 억제
WO2010097800A1 (en) * 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
BR112012000100B1 (pt) * 2009-07-09 2019-10-15 Alternapak Holding B.V. Material laminado de embalagem para recipientes de líquidos, fita de tiras para recipientes de líquidos, método de fabricação de material de embalagem e método de fabricação de um recipiente
RU2564131C2 (ru) * 2009-07-10 2015-09-27 ТромбоДженикс НВ Варианты плазминогена и плазмина
EP2480249B1 (en) * 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmin for the treatment of filtration failure after trabeculectomy

Also Published As

Publication number Publication date
ES2628321T3 (es) 2017-08-02
EP2785739B1 (en) 2017-03-15
WO2013079713A1 (en) 2013-06-06
AU2012321082B2 (en) 2015-03-12
EP2785739A1 (en) 2014-10-08
DK2785739T3 (en) 2017-07-03
US20130195889A1 (en) 2013-08-01
US9089552B2 (en) 2015-07-28
AU2012321082A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
GB201121308D0 (en) Process
GB201111595D0 (en) Improved process
GB201103499D0 (en) Process
GB201107072D0 (en) Process
PL2793599T3 (pl) Sposób
GB201211947D0 (en) Early entry
ZA201305221B (en) Process
GB201218123D0 (en) Process
GB201121557D0 (en) Process
GB201112051D0 (en) Process
GB201107073D0 (en) Process
IL229126A0 (en) process
GB201301348D0 (en) Early entry
GB201218124D0 (en) Process
GB201218121D0 (en) Process
PT2726454T (pt) Processo
GB201103092D0 (en) Process
GB201211946D0 (en) Early Entry
GB201107221D0 (en) Process
PL2785739T3 (pl) Poprawa wyniku trabekulektomii
SG11201403684YA (en) Process
GB201301301D0 (en) Early entry
GB201100215D0 (en) Projecting project outcome
GB201112370D0 (en) Process
GB2493491B (en) Process